Karyopharm Completes Enrollment in Phase 3 SENTRY Trial
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a company renowned for its innovations in cancer therapies, has finalized enrollment in the critical Phase 3 SENTRY trial. This trial evaluates the effectiveness of selinexor when used in conjunction with ruxolitinib for patients with myelofibrosis who have not yet received JAK inhibitors.
Pioneering Combination Therapy
Richard Paulson, the President and CEO of Karyopharm, expressed enthusiasm about this milestone achievement. "Completing enrollment in the Phase 3 SENTRY trial is a significant step forward. We are eager to share the top-line results from this pivotal trial soon," Paulson remarked. The combination of selinexor and ruxolitinib is positioned to potentially be the first therapy of its kind approved to treat myelofibrosis, contingent on data outcomes.
Gratitude to Contributors
Dr. Reshma Rangwala, Karyopharm's Chief Medical Officer, highlighted the collaborative effort behind this trial. “I want to extend my deepest appreciation to the patients and their families, the investigators, and the hardworking Karyopharm team for their invaluable contributions,” she noted. This trial seeks to deepen the understanding of myelofibrosis treatment, emphasizing the impact of XPO1 inhibition in managing this disease.
Community Support and Expectations
Kapila Viges, from the MPN Research Foundation, shared the community's anticipation for the trial’s results. “The myelofibrosis community desperately requires more effective therapeutic alternatives,” Viges stated, underscoring the importance of improving patient outcomes beyond what is currently available.
About the SENTRY Trial
The SENTRY trial, identified as XPORT-MF-034, assesses a weekly dosage of 60 mg of selinexor alongside ruxolitinib against a placebo plus ruxolitinib in patients new to JAK inhibitors. With a total of 353 participants, the trial’s co-primary endpoints include a minimum 35% spleen volume response rate at week 24 and tracking the average changes in total symptom scores over a 24-week period.
Understanding Myelofibrosis
Myelofibrosis is a rare type of blood cancer, impacting around 20,000 individuals in the United States alone. This condition leads to significant complications such as fibrosis of the bone marrow, anemia, and splenomegaly, which significantly reduce quality of life. Currently, the only available therapies are JAK inhibitors, with patients frequently facing challenges related to anemia and transfusion dependence.
The Promise of Selinexor
XPOVIO (selinexor) is Karyopharm’s flagship product, categorized as the first oral exportin 1 (XPO1) inhibitor that targets cancer cell growth mechanisms. Selinexor has shown substantial promise across various oncology indications, securing several approvals both domestically and internationally.
Contact Information and Additional Resources
Individuals seeking further details about Karyopharm's clinical endeavors or product information are encouraged to reach out to their Medical Information department via telephone at +1 (888) 209-9326.
Frequently Asked Questions
What is the Phase 3 SENTRY trial about?
The SENTRY trial evaluates the combination of selinexor and ruxolitinib in treating myelofibrosis patients who have not yet received JAK inhibitors.
What are the co-primary endpoints of this trial?
The co-primary endpoints are spleen volume response rate of at least 35% at week 24 and the average change in total symptom scores over 24 weeks.
How many patients are enrolled in the SENTRY trial?
A total of 353 patients are enrolled in the Phase 3 SENTRY trial.
What is the significance of selinexor in myelofibrosis treatment?
Selinexor has the potential to redefine treatment for myelofibrosis by being part of the first combination therapy approved for this condition.
How can I learn more about Karyopharm’s products?
For more information, you can contact Karyopharm’s Medical Information department or visit their official website.
